August 2021- Patient-reported outcomes (PROs) that assess health-related quality of life (HRQoL) are increasingly important components of cancer care and research that are infrequently used in sub-Saharan Africa (SSA). We administered the Chichewa Pediatric Patient-Reported Outcome Measurement Information System Pediatric (PROMIS)-25 at diagnosis, active treatment, and follow-up among pediatric lymphoma patients in Lilongwe, Malawi. Mean … Read more

August 2020- SERIES: People living with HIV or AIDS are at increased risk of Hodgkin and non-Hodgkin lymphoma compared with HIV-negative individuals. Data on the risk of multiple myeloma or leukaemia are inconsistent and of low quality but the risk does not seem to be increased. Specific haematological malignancies occur in different contexts of age, … Read more

March 2020- COMMENTARY: As governments in sub-Saharan Africa (SSA) expand access to effective antiretroviral therapy (ART) for HIV-infected patients, cancer is becoming an increasingly important cause of preventable death in the region. According to the Global Burden of Disease study, cancer is now the second leading cause of death worldwide, and, despite decreases in cancer … Read more

February 2020-This study provides among the first molecular characterizations of DLBCL from SSA, demonstrates marked gene expression differences by HIV status, and identifies genomic and immunophenotypic characteristics that can inform future basic and clinical investigations.

April 2020 – Breast cancer incidence in sub-Saharan Africa is increasing, and the region has the highest age-standardized breast cancer mortality rate worldwide. In a setting where breast cancer data are limited, our findings indicate that late stage presentation, HER2-enriched and triple-negative subtypes, and HIV coinfection were associated with mortality and were more prevalent in … Read more

January 2020 – Aggressive NHL is among the most common cancers in SSA where CHOP is the standard treatment and outcomes are poor. We treated patients with a modified EPOCH regimen with moderate outcomes. Results indicate that this regimen was feasible and effective in a small cohort and suggest EPOCH with setting-appropriate modifications may be … Read more

November 2019 – Although plasma EBV DNA measurement has established prognostic utility in EBV‐driven lymphomas, findings from this study suggest that EBV reactivation in nontumor cells is a poor prognostic finding even in HIV‐positive patients with convincingly EBV‐negative DLBCL.

October 2019 – Increasing access to conventional cancer treatment in low-income countries is an important public health initiative to address the global burden of cancer. Our findings indicate that cancer patients in our cohort rely on a pragmatic and experience-based treatment selection process and provide insights to the various factors that influence T&CM use among cancer … Read more

July 2019 – Cost analysis of treating diffuse large B-cell lymphoma (DLBCL) in Malawi indicates that per-patient cost of first-line treatment of DLBCL in Malawi is low relative to high-income countries, suggesting that investments in fixed-duration, curative-intent DLBCL treatment may be attractive in sub-Saharan Africa.

June 2019 – This article highlights the important role of cancer care and research outside the United States, particularly in low- and middle-income countries, in furthering innovative solutions for cancer that can be applied worldwide.